Skip to main content
SpringerLink
Log in

Medikamentöse Behandlung primärer Hyperlipoproteinämien

Drug treatment of primary hyperlipoproteinemia

  • Übersichten
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Cardiovascular disease has become the major cause of death in the Western countries. There is strong evidence that elevations of serum lipids contribute to the pathogenesis of premature atherosclerosis. The classification of the hyperlipoproteinemias has been most beneficial as a guide to development of dietary and pharmacological regimens for lowering serum lipid concentrations. The results of dietary and drug prevention trials are discussed. Insight into the mechanisms involved in lipoprotein metabolism as well as the mode of action and of side-effects of hypolipidemic drugs is reviewed. Using present knowledge of heart disease research, it is reasonable to suggest dietary and drug treatments for the high risk patient.

Zusammenfassung

Cardiovasculäre Erkrankungen sind die Haupttodesursache in den westlichen Ländern. Es ist erwiesen, daß Erhöhungen der Serumlipide zur frühzeitigen Entstehung der Arteriosklerose beitragen. Mit der Klassifikation der Hyperlipoproteinämien entstand die Grundlage für gezielte diätetische und pharmakologische Behandlungskonzepte zur Senkung der Serumlipidkonzentrationen. Es werden die Ergebnisse medikamentöser und diätetischer Präventivstudien diskutiert und die Erkenntnisse über den Stoffwechsel der Lipoproteine sowie Wirkungsweise und Nebenwirkungen der gebräuchlichsten lipidsenkenden Medikamente dargestellt. Es ist zum gegenwärtigen Zeitpunkt berechtigt, Patienten mit besonderer Disposition zur frühzeitigen Arteriosklerose diätetisch und medikamentös zu behandeln.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Rider. A.K.: Should hyperlipoproteinemia be treated in patients with coronary heart disease. JAMA233, 275–277 (1975)

    PubMed  Google Scholar 

  2. Ahrens, E.H., Jr.: The management of hyperlipidemia: whether, rather than how. Ann. Int. Med.85, 87–93 (1976)

    PubMed  Google Scholar 

  3. Miettinen, M., Turpeinen, O., Karvonen, M.J. et al.: Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. Lancet2, 835–838 (1972)

    PubMed  Google Scholar 

  4. Turpeinen, O., Miettinen, M., Karvonen, M.J. et al.: Dietary prevention of coronary heart disease. Amer. J. Clin. Nutr.21, 255–276 (1968)

    PubMed  Google Scholar 

  5. Oliver, M.F.: Ischaemic heart disease: a secondary prevention trial using clofibrate. Brit. Med. J.4, 775–784 (1971)

    PubMed  Google Scholar 

  6. Dewar, H.A.: Trial of clofibrate in the treatment of ischaemic heart disease. Brit. Med. J.4, 767–775 (1971)

    PubMed  Google Scholar 

  7. Krasno, L.R., Kidera, G.J.: Clofibrate in coronary heart disease: effect on morbidity and mortality. JAMA219, 845 (1972)

    PubMed  Google Scholar 

  8. Stamler, J.: The Coronary Drug Project. JAMA231, 360–381 (1975)

    PubMed  Google Scholar 

  9. Kannel, W.B., Castelli, W.P., Gordon, T., McNamara, P.M.: Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann. Int. Med.55, 33–50 (1961)

    PubMed  Google Scholar 

  10. Truett, J., Cornfield, J., Kannel, W.B.: Multivariate analysis of risk of coronary heart disease in Framingham. J. Chronic Dis.20, 511–524 (1967)

    PubMed  Google Scholar 

  11. Kannel. W.B., Castelli, W.P., Gordon, T.: Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann. Int. Med.74, 1–12 (1971)

    PubMed  Google Scholar 

  12. Patterson, D., Slack, J.: Lipid abnormalities in male and female survivors of myocardial infarction and their first degree relatives. Lancet1, 393–399 (1972)

    PubMed  Google Scholar 

  13. Epstein, F.H., Ostrander, L.D.: Detection of individual susceptibility toward coronary artery disease. Progr. Cardiovasc. Dis.13, 324–342 (1971)

    Google Scholar 

  14. Goldstein, J.L., Hazzard, W.R., Schrott, H.G.: Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J. clin. Invest.52, 1533–1543 (1973)

    PubMed  Google Scholar 

  15. D.S. Fredrickson, R.I. Levy: Familial hyperlipoproteinemia. In: The Metabolic Basis of Inherited Disease. J.B. Stanbury, J.B. Wyngaarden, D.S. Fredrickson (eds.), McGraw-Hill, New York 1972, 545

    Google Scholar 

  16. Anitschkow, N.: Über die Veränderung der Kaninchenaorta bei experimenteller Cholesterinsteatose. Beitr. Path. Anat.56, 379–404 (1913)

    Google Scholar 

  17. Wissler, R., Eilert, M.C., Schroeder, M.A., Cohen, L.: Production of lipomatous and atheromatous arterial lesions in the albino rat. Arch. Path.57, 333–351 (1954)

    Google Scholar 

  18. Kritchevsky, D.: Experimental atherosclerosis. In: Lipid Pharmacology. R. Paoletti (ed.), Academic Press Inc., New York 1964, 63–130

    Google Scholar 

  19. Ross, R., Harker, L.: Hyperlipidemia and atherosclerosis. Science193, 1094 (1976)

    PubMed  Google Scholar 

  20. Bencze, W.L., Hess, R., Destevens, G.: Hypolipidemic agents. In: Progress Drug Res. Jucker, E. (ed.), Birkhaeuser, Basel 1969, 13, 217

    Google Scholar 

  21. Fredrickson, D.S., Levy, R.I., Lees, R.S.: Fat transport. An integrated approach to mechanisms and disorders. New Engl. J. Med.276, 32–44, 94–103, 148–156, 215–226, 273–281 (1967)

    Google Scholar 

  22. Greten, H.: Klinik und Klassifizierung primärer Hyperlipoproteinämien. In: Fettstoffwechselstörungen, ihre Erkennung und Behandlung. G. Schettler (ed.), Thieme-Verlag, Stuttgart 1971, 4

    Google Scholar 

  23. Seidel, D.: Plasmalipoproteine — Funktion und Charakterisierung. In: Fettstoffwechselstörungen, ihre Erkennung und Behandlung. G. Schettler (ed.), Thieme-Verlag, Stuttgart 1971, 24

    Google Scholar 

  24. Morrisett, J.D., Jackson, R.L., Gotto, A.M.: Lipoproteins — structure and function. Ann. Rev. Biochem.44, 183 (1975)

    PubMed  Google Scholar 

  25. Middelhoff, G., Augustin, J., Klose, G., Greten, H.: Lipid-Protein-Wechselwirkungen menschlicher Apolipoproteine — Entwicklung von Lipoproteinmodellen. Klin. Wschr.55, 149 (1977)

    PubMed  Google Scholar 

  26. Levy, R.I., Blum, C.B., Schaefer, E.J.: The composition, structure and metabolism of high density lipoprotein. In: Lipoprotein Metabolism. H. Greten (ed.), Springer-Verlag Berlin Heidelberg New York 1976, 56

    Google Scholar 

  27. Miller, G.J., Miller, N.E.: Plasma-high-density-lipoprotein concentration and development of ischemic heart disease. Lancet4, 16 (1975)

    Google Scholar 

  28. Stein, O., Stein, Y.: Comparative uptake of rat and human serum low-density and high-density lipoproteins by rat aortic smooth muscle cells in culture. Circulat. Res.36, 436 (1975)

    PubMed  Google Scholar 

  29. Greten, H.: Lipoprotein Metabolism. Springer-Verlag Berlin Heidelberg New York 1976

    Google Scholar 

  30. Eisenberg, S.: Lipoprotein metabolism and hyperlipidemia. In: Atherosclerosis Reviews. R. Paoletti, A.M. Gotto (eds.), Raven Press, New York 1976, 23

    Google Scholar 

  31. Augustin, J., Middelhoff, G., Brown, W.V.: Metabolismus der Lipoproteine. In: Handbuch der Inneren Medizin, Band VII/4. G. Schettler, H. Greten, G. Schlierf, D. Seidel (eds.), Springer-Verlag Berlin Heidelberg New York 1976, 219

    Google Scholar 

  32. Havel, J.R.: Mechanisms of hyperlipoproteinemia. Arch. Exp. Biol. Med.26, 57 (1972)

    Google Scholar 

  33. Greten, H.: Untersuchungen zum Stoffwechsel menschlicher Chylomikronen. Klin. Wschr.52, 947 (1974)

    PubMed  Google Scholar 

  34. Goldstein, J.L., Brown, M.S.: Familial hypercholesterolemia: a genetic regulatory defect in cholesterol metabolism. Amer. J. Med.58, 147 (1975)

    PubMed  Google Scholar 

  35. Bergen, S.S., Jr., van Itallie, T.B., Tenneat, D.M., Sebrell, W.H.: Effect of anion exchange resin on serum cholesterol in man. Proc. Soc. Exp. Biol.102, 676 (1959)

    Google Scholar 

  36. Carey, J.B.: Lowering of serum bile acid concentration and relief of pruritus of jaundiced patients fed a bile acid sequestering resin. J. Lab. Clin. Med.36, 797 (1960)

    Google Scholar 

  37. Bergen, S.S., Jr., van Itallie, T.B.: Approaches to the treatment of hypercholesterolemia. Ann. Intern. Med.38, 355 (1963)

    Google Scholar 

  38. Parkinson, T.M.: Hypolipidemic effects of orally administered dextran and cellulose anion exchanges on cockerels and dogs. J. Lipid Res.8, 24 (1967)

    PubMed  Google Scholar 

  39. Howard, A.N., Hyanes, D.E.: Combined use of clofibrate and cholestyramine or DEAE-Sephadex in hypercholesterolaemia. Brit. Med. J.3, 25 (1971)

    PubMed  Google Scholar 

  40. Nye, E.R., Jackson, D., Hunter, J.D.: Treatment of hypercholesterolaemia with colestipol, a bile sequestering agent. New Zeal. N.Z. Med.22, 235 (1971)

    Google Scholar 

  41. Parkinson, T.M., Gundersen, K., Nelson, N.A.: Effect of colestipol (U-26, 597 A), a new bile acid sequestrant on serum lipids in experimental animals and man. Atherosclerosis II, 531 (1970)

    Google Scholar 

  42. Glueck, C.J., Ford, S., Scheel, D., Steiner, P.: Colestipol and cholestyramine resin. J. Amer. Med. Ass.222, 676 (1972)

    Google Scholar 

  43. Carey, J.B., Jr., Williams, G.: Relief of pruritus of jaundice with a bile-acid sequestering resin. J. Amer. Med. Ass.176, 432 (1961)

    Google Scholar 

  44. Miettinen, T.A.: Drugs affecting bile acid and cholesterol excretion. In: Atherosclerosis, Proc. 2nd Int. Symp., R.J. Jones (ed.), Springer-Verlag Berlin Heidelberg New York 1970, 508

    Google Scholar 

  45. Moore, R.B., Crane, C.A., Frantz, I.D., Jr.: Effect of cholestyramine on the fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient. J. clin. Invest.47, 1664 (1968)

    PubMed  Google Scholar 

  46. Grundy, S.M., Ahrens, E.H., Jr., Salen, G.: Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J. Lab. clin. Med.78, 94 (1971)

    PubMed  Google Scholar 

  47. Howard, R.P., Brusco, O.J., Furman, R.H.: Effect of cholestyramine administration on serum lipids and on nitrogen balance in familial hypercholesterolemia. J. Lab. clin. Med.68, 12 (1966)

    PubMed  Google Scholar 

  48. Lees, A.M., McCluskey, M.A., Lees, R.S.: Results of colestipol therapy in Type II hyperlipoproteinemia. Atherosclerosis24, 129 (1976)

    PubMed  Google Scholar 

  49. Gustafson, A., Langer, A.: Treatment of HLP Type II a with a new anion exchange resin secholex. Europ. J. clin. Pharmacol.7, 65 (1974)

    Google Scholar 

  50. Howard, A.N., Courtenay, E.R.J.: Secholex, clofibrate and taurine in hyperlipidemia. Atherosclerosis20, 105 (1974)

    PubMed  Google Scholar 

  51. Ritland, S., Fausa, O., Gjone, E., Blomhoff, J.P., Skrede, S., Lanner, A.: Effect of treatment with a bile sequestering agent (Secholex®) on intestinal absorption, duodenal bile acids and plasma lipids. Scand. J. Gastroent.10, 791 (1975)

    PubMed  Google Scholar 

  52. Nikkilä, E.A., Miettinen, T.A., Lanner, A.: Treatment of hypercholesterolemia with secholex. A long-term clinical trial and comparison with cholestyramine. Atherosclerosis24, 407 (1976)

    PubMed  Google Scholar 

  53. Levy, R.I., Fredrickson, D.S., Stone, N.J. et al.: Cholestyramine in Type II hyperlipoproteinemia — a double blind trial. Ann. Int. Med.79, 51 (1973)

    PubMed  Google Scholar 

  54. Thompson, G.R., Mac Mahon, M., Claes, P.: Precipitation by neomycin compounds of fatty acid and cholesterol from mixed micellar solutions. Europ. J. clin. Invest.1, 40 (1970)

    PubMed  Google Scholar 

  55. Grundy, S.M., Ahrens, E.H., Jr.: Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods. J. Lipid Res.10, 91 (1969)

    PubMed  Google Scholar 

  56. Lees, R.S., Lees, A.M.: Effects of sitosterol therapy on plasma lipid and lipoprotein concentrations. In: Lipoprotein Metabolism, H. Greten (ed.). Springer-Verlag Berlin Heidelberg New York 1976, 119

    Google Scholar 

  57. Oster, P., Schlierf, G., Heuck, C.C. et al.: Sitosterin bei familiärer Hyperlipoproteinämie Typ II. Dtsch. Med. Wschr.101, 1308 (1976)

    PubMed  Google Scholar 

  58. Boyd, G.S., Oliver, M.F.: Effect of certain thyroxine analogues on the serum lipids in human subjects. J. Endocr.21, 33 (1960)

    Google Scholar 

  59. Oliver, M.F., Boyd, G.S.: Reduction of serum cholesterol by dextrothyroxine in men with coronary heart disease. Lancet1, 783 (1961)

    PubMed  Google Scholar 

  60. Strisower, B., Gofman, J.W., Rubin, L., Rosenthal, D., De Lalla, O.: The effect of desiccated thyroid on the hyperlipoproteinemia of xanthoma tendinosum. Amer. J. Med. Sci.239, 71 (1960)

    PubMed  Google Scholar 

  61. Rosenman, R.H., Byers, S.O., Frialman, M.: Mechanisms responsible for altered blood cholesterol content in deranged thyroid states. J. clin. Endocrin.12, 1287 (1952)

    Google Scholar 

  62. Kritchevsky, D.: Influence of thyroid hormones and related compounds on cholesterol biosynthesis and degradation. Metabolism9, 984 (1960)

    PubMed  Google Scholar 

  63. Rabinowitz, J.L., Rodman, T., Myerson, R.M.: Effect of dextrothyroxine on metabolism of C14-labeled cholesterol and tripalmitin. JAMA 118 (1963)

  64. Simons, L.A., Myant, N.B.: The effect of D-thyroxine on the metabolism of cholesterol in familial hyperbetalipoproteinemia. Atherosclerosis19, 103 (1974)

    PubMed  Google Scholar 

  65. Miéttinen, T.A.: Mechanism of serum cholesterol reduction by thyroid hormones in hypothyroidism. J. Lab. clin. Med.71, 537 (1968)

    PubMed  Google Scholar 

  66. Nikkilä, E.A., Kekki, M.: Plasma triglyceride metabolism in thyroid disease. J. clin. Invest.51, 2103 (1972)

    PubMed  Google Scholar 

  67. Scheiffele, E., Schultze, K.W.: Letters to the editor. JAMA8, 221 (1972)

    Google Scholar 

  68. Klemens, U.H., v. Löwis of Menar, P.: Behandlung primärer Hyperlipoproteinämien vom Typ II a, II b mit hochgereinigtem D-Thyroxin. Dtsch. Med. Wschr.99, 487 (1974)

    PubMed  Google Scholar 

  69. Bommer, J., Speders, H., Ehrke, V.: Behandlung der Hypercholesterinämie nach Herzinfarkt mit D-Thyroxin. Münch. Med. Wschr.4, 139 (1975)

    Google Scholar 

  70. Koschinsky, T., Vogelberg, K.H., Gries, F.A.: Therapie primärer Hyperlipoproteinämie II a und II b mit D-Thyroxin. Dtsch. Med. Wschr.11, 494 (1974)

    Google Scholar 

  71. Rakow, A.D., Ditschuneit, H.H., Küter, E., Ditschuneit, H.: Der Einfluß von D-Thyroxin-Na (Dynothel) auf die Hypercholesterinämie. Verh. Dtsch. Ges. Inn. Med.80, 1259 (1974)

    PubMed  Google Scholar 

  72. Rakow, A.D., Klör, H.U., Küter, E., Ditschuneit, H.H., Ditschuneit, H.: Treatment of Type II hyperlipoproteinemia with D-Thyroxine. Atherosclerosis24, 369 (1976)

    PubMed  Google Scholar 

  73. Schwartzkopff, W., Russ, E.: Langzeit-Therapie von Hyperlipoproteinämien der Typen II a, II b mit Etiroxat. Dtsch. Med. Wschr.100, 815 (1975)

    PubMed  Google Scholar 

  74. Altschul, R., Hoffer, A., Stephen, J.D.: Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys.54, 558 (1955)

    Google Scholar 

  75. Parsons, W.B., Jr.: Chemotherapy of hyperlipidemia. Mayo Clin. Proc.40, 822 (1965)

    PubMed  Google Scholar 

  76. Carlson, L.A., Okö, J., Ostman, J.: Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia during the first week of treatment. J. Atheroscler. Res.8, 667 (1968)

    PubMed  Google Scholar 

  77. Parsons, W.B., Jr.: Treatment of hypercholesterolemia by nicotinic acid: progress report with a review of studies regarding mechanism of action. Arch. Int. Med.107, 639 (1961)

    Google Scholar 

  78. Gey, K.F., Carlson, L.A.: Metabolic effects of nicotinic acid and its derivatives. Hans Huber Verlag, Bern 1971

    Google Scholar 

  79. Langer, T., Levy, R.I.: Effect of nicotinic acid on beta lipoprotein metabolism (Abstr.). Clin. Res.18, 458 (1970)

    Google Scholar 

  80. Magide, A.A., Myant, N.B.: Effect of nicotinic acid on cholesterol metabolism in monkeys. Clin. Sci. Molec. Med.46, 527 (1972)

    Google Scholar 

  81. Magide, A.A., Myant, N.B., Reichl, D.: The effect of nicotinic acid on the metabolism of the plasma lipoproteins of rhesus monkeys. Atherosclerosis21, 205 (1975)

    PubMed  Google Scholar 

  82. Carlson, L.A.: Inhibition of the mobilization of free fatty acids from adipose tissue. Ann. N.Y. Acad. Sci.131, 119 (1965)

    PubMed  Google Scholar 

  83. Miettinen, T.A.: Methods for evaluation of hypolipidemic drugs in man: mechanisms of their action. In: Lipid Pharmacology, Vol. II, R. Paoletti and C.J. Glueck (eds.). Academic Press, New York 1976, 83

    Google Scholar 

  84. Miettinen, T.A.: Effect of nicotinic acid on catabolism and synthesis of cholesterol in man. Clin. Chim. Acta20, 43 (1968)

    PubMed  Google Scholar 

  85. Zöllner, N., Gudensi, M.: Behandlung der Hypercholesterinämie mit Beta-Pyridylcarbinol. I. Biochemie und klinische Ergebnisse. Med. Klin.61, 1996 (1966)

    PubMed  Google Scholar 

  86. Nelemans, F.A.: Report on a double-blind investigation into the influence of β-pyridylcarbinol on the cholesterol level of the blood. Arzneimittel-Forsch. (Drug Res.)22, 1410 (1972)

    Google Scholar 

  87. Carlson, L.A., Oro, L.: Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis18, 1 (1973)

    PubMed  Google Scholar 

  88. Thorp, J.M., Warnnig, W.S.: Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature194, 948 (1962)

    PubMed  Google Scholar 

  89. Rueghamer, W.R., Ryan, N.T., Richert, D.A., Westerfeld, W.W.: The effects of p-chlorophenoxyisobutyrate on the turnover rate and distribution of thyroid hormone in the rat. Biochem. Pharmacol.19, 613 (1969)

    Google Scholar 

  90. Cheng, C.Y., Feldman, E.B.: Clofibrate, inhibitor of intestinal cholesterogenesis. Biochem. Pharmacol.20, 3509 (1971)

    PubMed  Google Scholar 

  91. White, L.W.: Regulation of hepatic cholesterol biosynthesis by clofibrate administration. J. Pharmacol. Exp. Theo.178, 361 (1971)

    Google Scholar 

  92. Adams, L.L., Webb, W.W., Fallon, H.J.: Inhibition of hepatic triglyceride formation by clofibrate. J. clin. Invest.50, 2339 (1971)

    PubMed  Google Scholar 

  93. Duncan, C.H., Best, M.M.: Inhibition of hepatic secretion of triglycerides by chlorophenoxyisobutyrate (CPIB). Circulation30, 111 (1964)

    Google Scholar 

  94. Gould, R.G., Swyryd, E.H., Coan, B.J. et al.: Effects of chlorophenoxyisobutyrate (CPIB) on liver composition and triglyceride synthesis in rats. J. Atheroscler. Res.6, 555 (1966)

    Google Scholar 

  95. Rifkind, B.M.: Effect of CPIB ester on plasma free fatty acid levels in man. Metabolism15, 673 (1966)

    PubMed  Google Scholar 

  96. Grundy, S.M., Ahrens, E.H., Jr., Salen, G.: Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J. Lipids Res.13, 531 (1972)

    Google Scholar 

  97. Kather, H., Simon-Crisan, G., Simon, B.: Inhibition of human fat cell adenylate cyclase by clofibrate. Horm. Metabol. Res.8, 146 (1976)

    Google Scholar 

  98. Schettler, G., Mordasini, R., Zipperle, G., Klar, E., Laible, V., Greten, H.: Der Wirkungsmechanismus synthetischer Heparinoide — Resultate bei Patienten mit Hypertriglyceridämie. Dtsch. Med. Wschr., in press (1977)

  99. Beaumont, J.L., Bachet, C.: Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters. Its significance for the mechanism of lipid lowering by clofibrate and related drugs. Atherosclerosis25, 255 (1976)

    PubMed  Google Scholar 

  100. Langer, T., Levy, R.I.: Acute muscular syndrome associated with administration of clofibrate. New Engl. J. Med.279, 856 (1968)

    PubMed  Google Scholar 

  101. Thistle, J.L., Schoenfield, L.J.: Induced alterations in composition of bile of persons having cholelithiasis. Gastroenterology61, 488 (1971)

    PubMed  Google Scholar 

  102. Summerfield, J.A., Elias, E., Sherlock, S.: Effects of clofibrate in primary biliary cirrhosis, hypercholesterolemia and gallstones. Gastroenterology69, 993 (1975)

    Google Scholar 

  103. Levy, R.I., Quarfordt, S.H., Brown, W.V. et al.: The efficacy of clofibrate (CPIB) in familial hyperlipoproteinemias. In: Drugs Affecting Lipid Metabolism, W.L. Holmes, L.A. Carlson, R. Paoletti (eds.), Proceedings. Plenum Press, New York 1969, 377

    Google Scholar 

  104. Schlierf, G., Kahlke, W., Reinheimer, W.: Langzeitbehandlung primärer Hyperlipidämien mit Clofibrat. Fortschritte Med.88, 907 (1970)

    Google Scholar 

  105. Hellman, L., Zumoff, B., Kessler, G. et al.: Reduction of cholesterol and lipids in man by ethyl-p-chlorophenoxyisobutyrate. Ann. Int. Med.59, 477 (1963)

    PubMed  Google Scholar 

  106. Oliver, M.F.: Further observations on the effects of atromid and of ethyl chlorophenoxybutyrate on serum lipid levels. J. Atheroscler. Res.3, 427 (1963)

    Google Scholar 

  107. Alaupovic, R.P., Brusco, O.J., Furman, R.H.: Effects of ethyl chlorophenoxyisobutyrate, alone or with androsterone (Atromid) on serum lipids, lipoproteins and related metabolic parameters in normal and hyperlipidemic subjects. J. Atheroscler. Res.3, 482 (1963)

    Google Scholar 

  108. Best, M.M., Duncan, C.H.: Reduction of serum triglycerides and cholesterol by ethyl-p-chlorophenoxyisobutyrate (CPIB). Amer. J. Cardiol.15, 230 (1965)

    PubMed  Google Scholar 

  109. Howard, R.P. et al.: Effects of ethyl chlorophenoxyisobutyrate alone or with androsterone (Atromid) on serum lipids, lipoproteins and related metabolic parameters in normal and hyperlipemic subjects. J. Atheroscler. Res.3, 482 (1963)

    Google Scholar 

  110. von Löwis of Menar, P., Klemens, U.H.: Behandlung primärer Hyperlipoproteinämien II a, II b, III und IV mit Clofibrat. Dtsch. Med. Wschr.98, 2328 (1973)

    PubMed  Google Scholar 

  111. Schwartzkopf, W., Hoffmann, H., Kaestner, W.: Vergleichende Untersuchung zur Lipidsenkung durch Clofibrinsäure und Clofibrat bei Hyperlipoproteinämien. Med. Welt26, 2308 (1975)

    PubMed  Google Scholar 

  112. Wolfram, G., Keller, C., Kilami, S., Zollmar: First clinical experiences in therapy of hyperuricemia and hyperlipidemia. Verh. Dtsch. Ges. Inn. Med.79, 2191 (1973)

    Google Scholar 

  113. Rees, E.D., Hamilton, R.D., Kanner, I.F. et al.: Halofenate in the treatment of Type II hyperlipoproteinemia. Double blind comparison with clofibrate. Atherosclerosis24, 537

  114. Navarette, V.N., Torres, H.J., Lee, D.B., Soria, J.: Treatment with phenformin of hypercholesterolemia and hypertriglyceridemia in non diabetic subjects. Excerpta Med. Int. Congr. Ser.140, 45 (1967)

    Google Scholar 

  115. Stout, R.W., Brunzell, J.D., Porte, D., Bierman, L.E.: Effect of phenformin on lipid transport in hypertriglyceridemia. Metabolism9, 815 (1974)

    Google Scholar 

  116. Lang, P.D., Vollmar, J., Klemens, U.H. et al.: Die lipidsenkende Wirkung von Phenformin bei primärer Hyperlipoproteinämie Typ IV. Dtsch. Med. Wschr.48, 2280 (1973)

    Google Scholar 

  117. Vogelberg, K.H.: Die Kombination von Clofibrat und Phenformin in der Behandlung endogener Hypertriglyceridämien. Dtsch. Med. Wschr.101, 1868 (1976)

    PubMed  Google Scholar 

  118. Blaton, V., Peeters, H.: Effect of unsaturated phosphatidylcholine on the lipoprotein lipase activity in vitro. In: Atherosclerosis III, G. Schettler, A. Weizel (eds.). Springer-Verlag Berlin Heidelberg New York 1974, 565

    Google Scholar 

  119. Ditschuneit, H., Klör, H.-U., Ditschuneit, H.H.: Effects of essential phospholipids on the carbohydrate-induced hypertriglyceridemia. In: Phosphatidylcholine, H. Peeters (ed.), Springer-Verlag Berlin Heidelberg New York 1976, 98

    Google Scholar 

  120. Blaton, V., Declercq, B., Vandamme, D., Soetewey, F., Peeters, H.: The human plasma lipids and lipoproteins under influence of EPL-therapy. In: Phosphatidylcholine, H. Peeters (ed.), Springer-Verlag Berlin Heidelberg New York 1976, 125

    Google Scholar 

  121. Peeters, H., Blaton, V., Soetewey, F., Declercq, B., Vandamme, D.: Wirkung der „essentiellen“ Phospholipide auf Plasmalipide und Fettsäuren bei Typ II Hyperlipoproteinämie. Münch. Med. Wschr.31, 1358 (1973)

    Google Scholar 

  122. Howard, A.N., Patelski, J., Bowyer, D.E., Gresham, G.A.: Phospholipids in experimental atherosclerosis. In: Phospholipids. Thieme-Verlag Stuttgart 1972, 79

    Google Scholar 

  123. Marmorston, J., Moore, F.J., Hopkins, C.E., Kuzma, O.T., Weiner, J.: Clinical studies of long term estrogen therapy in men with myocardial infarction. Proc. Soc. Exp. Biol.110, 400 (1962)

    Google Scholar 

  124. Glueck, C.J., Scheel, D., Fishback, J., Steiner, P.: Progestagens, anabolic-androgenic compounds, estrogens: effects on triglycerides and postheparin lipolytic enzymes. Lipids7, 110 (1972)

    PubMed  Google Scholar 

  125. Best, M.M., Duncan, C.H.: Effects of clofibrate and dextrothyroxine singly and in combination on serum lipids. Arch. Intern. Med.118, 97 (1966)

    PubMed  Google Scholar 

  126. Courtenay Evans, R.J., Howard, A.N., Hyams, D.E.: An effective treatment of hypercholesterolaemia using a combination of secholex and clofibrate. Angiology24, 22 (1973)

    PubMed  Google Scholar 

  127. Fellin, R., Baggio, G., Balestrieri, P.: Les effets du colestipol associé au clofibrate sur les lipides seriques dans l'hyperlipoproteinemie familiale du Type II. Rev. Franc. Endocrin. Clin.15, 445 (1974)

    Google Scholar 

  128. De Witt S. Grotman, Noble, R.P., Bell, R.B.: The effect of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man. J. clin. Invest.52, 2646 (1974)

    Google Scholar 

  129. Stein, E.A., Heimann, K.W.: Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperlipoproteinemia. South Afr. Med. J.49, 1252 (1975)

    Google Scholar 

  130. Färgeman, O.: Effects and side-effects of treatment of hypercholesterolemia with cholestyramine and neomycin. Acta Med. Scand.194, 165 (1973)

    PubMed  Google Scholar 

  131. Knüchel, F.: Wirkung eines neuen lipidsenkenden Medikamentes (Etofibrat) bei Hyperlipoproteinämie Typ II. Med. Welt25, 1766 (1974)

    PubMed  Google Scholar 

  132. Mann, S., Maisenbacher, H.-J.: Klinische Prüfung einer Kombination von Clofibrat und β-Pyridylcarbinol mit ungewöhnlicher Dosisrelation. Zeitschr. f. Allgemeinmed.24, 1066 (1975)

    Google Scholar 

  133. Leopold, G., Simane, Z., Stole, K.D., Breuer, J.: Vergleichende klinisch-pharmakologische Untersuchung der lipidsenkenden Wirkung von EMO 100 und Clofibrat. Med. Welt26 (N.F.), 1542 (1975)

    Google Scholar 

  134. Hernandez, A., Maisenbacher, H.J., Stoll, K.D.: Synergistische Wirkung einer Kombination von Clofibrat und β-Pyridylcarbinol im Verhältnis 20:1 bei der Behandlung primärer Hyperlipoproteinämie IIa, IIb und IV. Therapiewoche25, 36 (1975)

    Google Scholar 

  135. Wilke, H., Frahm, H.: Behandlung der Hyperlipoproteinämie Typen IIa, IIb, IV und V mit einer Clofibrat inositolnicotinat-Kombination — Ergebnisse einer Dreiphasenstudie. Münch. Med. Wschr.101, 401 (1976)

    Google Scholar 

  136. Schneider, J., Haase, W., Kaffarnik, H.: Feldstudie zur Lipidsenkung mit Etofibrat. Fortschr. Med. 785 (1976)

  137. Samuel, P., Holtzmann, C.M., Meilman, E., Sekowski, I.: Reduction of serum cholesterol and triglyceride levels by the combined administration of neomycin and clofibrate. Circulation XLI, 109 (1970)

  138. Montafis, C.D., Myant, N.B., Mancini, M., Oriente, P.: Cholestyramine and nicotinic acid in the treatment of familial hyperbetalipoproteinaemia in the homozygous form. Atherosclerosis14, 247 (1971)

    PubMed  Google Scholar 

  139. Kellner, R., Matzkies, F., Bey, G.: Medikamentöse Kombinationstherapie der Hyperlipoproteinämie. Fortschritte Med.93, 529 (1975)

    Google Scholar 

  140. Levy, R.I. et al.: Dietary and drug treatment of primary hyperlipoproteinemia. Ann. Int. Med.77, 267 (1972)

    PubMed  Google Scholar 

  141. Levy, R.I., Morganroth, J., Rifkind, B.M.: Drug therapy — treatment of hyperlipidemia. New Engl. J. Med.290, 1295 (1974)

    PubMed  Google Scholar 

  142. Schettler, G.: Behandlung der Hyperlipoproteinämien. Schriftenreihe der Bundesapothekerkammer zur wiss. Fortbildung, Werbe- und Vertriebsgesellschaft Deutscher Apotheker m.b.h., Frankfurt am Main 1976

    Google Scholar 

  143. Wollenweber, J.: Medikamentöse Therapie der Hyperlipidämien. Zeitschr. f. Allgemeinmed.52, 1674 (1976)

    Google Scholar 

  144. Ströhla, H.: Erfolgskontrolle der Hyperlipoproteinämiebehandlung in einer Lipidambulanz. Inaugural-Dissertation, Heidelberg 1974

    Google Scholar 

  145. Buchwald, H.: The development of the sub-total ileal bypass operation as a therapeutic approach to hypercholesterolemia and atherosclerosis: a review. Diseases Chest51, 459 (1976)

    Google Scholar 

  146. Starzl, T.E., Chase, H.P., Putnam, C.W., Porter, K.A.: Portocaval shunt in hyperlipoproteinemia. Lancet2, 940 (1973)

    PubMed  Google Scholar 

  147. Torsvik, H., Feldman, H.A., Fischer, J.E., Less, R.E.: Effects of intravenous hyperalimentation on plasmalipoproteins in severe familial hypercholesterolemia. Lancet1, 601 (1975)

    PubMed  Google Scholar 

  148. Thompson, G., Lowenthal, R., Myant, N.B.: Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet1, 7918 (1975)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinisches Institut für Herzinfarktforschung an der Medizinischen Universitätsklinik Heidelberg, Germany

    G. Klose, R. Mordasini, G. Middelhoff, J. Augustin & H. Greten

Authors
  1. G. Klose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Mordasini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Middelhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Augustin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Greten
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klose, G., Mordasini, R., Middelhoff, G. et al. Medikamentöse Behandlung primärer Hyperlipoproteinämien. Klin Wochenschr 56, 99–110 (1978). https://doi.org/10.1007/BF01478565

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01478565

Key words

Schlüsselwörter

Search

Navigation